CAS: 87233-61-2; 1-(2-Ethoxyethyl)-2-(4-Methyl-1,4-Diazepan-1-yl)-1H-Benzo[d]Imidazole

该化合物是主要用于治疗过敏结膜炎的眼科配方的抗口炎化合物,具有选择性的H1受体对抗性,有效阻断了导致过敏症状的抗体胺作用,其特征是能够减轻过敏性征,红度和过敏性导致眼睛肿胀;该物质一般是作为眼滴施用,允许最小系统吸收的局部行动;其化学结构包括一个管状环,有助于其药理特性;内脏一般是良好的,具有低副作用,尽管有些病人可能患有轻微的眼部刺激;该化合物在水中可溶解,有助于形成对眼部使用眼部的水溶液;

英文名称1-(2-Ethoxyethyl)-2-(4-Methyl-1,4-Diazepan-1-yl)-1H-Benzo[d]Imidazole
中文名称依美司丁
IUPAC名称1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)-1H-benzo[d]imidazole
其它别名1-(2-Ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole
CAS编号87233-61-2
MFCD编号:MFCD00865647
FDA UNII编号:9J1H7Y9OJV
分子式:C17H26N4O
分子量:302.42
产品CID: 1878328
产品分类原料药

相似结构搜索
产品信息参考;;
InChIKey: KBUZBQVCBVDWKX-UHFFFAOYSA-N
InChI=1S/C17H26N4O/c1-3-22-14-13-21-16-8-5-4-7-15(16)18-17(21)20-10-6-9-19(2)11-12-20/h4-5,7-8H,3,6,9-14H2,1-2H3…
计算化学: 氢键受体数4.0氢键供体数0.0可旋转键数5.0

物理性质

熔点148-151 °C
沸点446.6±55.0 °C at 760 mmHg
闪点223.9±31.5 °C
密度1.2±0.1 g/cm3
pKa:8.86±0.10(预测)
PSA:33.53
LogP:3.02
折射率1.595
蒸汽压0.0±1.1 mmHg at 25°C
溶解性DMSO: 125 mg/mL (413.35 Mm); Ethanol: 100 mg/mL (330.68 Mm)
外观形态黄色至棕色粘稠液体
储存条件2-8°C
产品应用依米司汀的用途:抗组胺药.

MSDS等安全信息

警示词Warning
危险描述H302-H315-H319-H335-
防范说明P261-P280-P301+P312-P302+P352-P305+P351+P338-

上下游产品

合成工艺路线路线简述

合成目标产物 Emedastine 主要起始原料 2-Chlorobenzimidazole
101954-20-5 = 87233-61-2
反应条件:1.1 Reagents: Formic Acid Solvents: Water; 30 Min,80 °C1.2 Reagents: Sodium Hydroxide Solvents: Water; Ph 10
标题:Copper-Catalysed C-H Functionalisation Gives Access To 2-Aminobenzimidazoles
作者:Clark,Peter R.; Et Al
参考文献:Organic & Biomolecular Chemistry 日期:2019 卷标:17(34) 页码:7943-7955]

4318-37-0 + 87233-54-3 = 87233-61-2 + 110-17-8 [标题:Reaction Conditions
标题:Synthesis Of 2-(4-Substituted-1-Piperazinyl)Benzimidazoles As H1-Antihistaminic Agents
作者:Iemura,Ryuichi; Et Al
参考文献:Journal Of Medicinal Chemistry 日期:1986 卷标:29(7) 页码:1178-83]

110-76-9 = 87233-61-2 + 110-17-8
反应条件:1.1 -2.1 Reagents: Sodium Hydroxide,Zinc Solvents: Ethanol,Water3.1 -4.1 Reagents: Phosphorus Oxychloride5.1 -
标题:Synthesis Of 2-(4-Substituted-1-Piperazinyl)Benzimidazoles As H1-Antihistaminic Agents
作者:Iemura,Ryuichi; Et Al
参考文献:Journal Of Medicinal Chemistry 日期:1986 卷标:29(7) 页码:1178-83]

2375311-04-7 = 87233-61-2
反应条件:1.1 Reagents: Hydrochloric Acid Solvents: Ethyl Acetate; 64 H,Rt1.2 Reagents: Sodium Bicarbonate Solvents: Water1.3 Reagents: Formic Acid Solvents: Water; 30 Min,80 °C1.4 Reagents: Sodium Hydroxide Solvents: Water; Ph 10
标题:Copper-Catalysed C-H Functionalisation Gives Access To 2-Aminobenzimidazoles
作者:Clark,Peter R.; Et Al
参考文献:Organic & Biomolecular Chemistry 日期:2019 卷标:17(34) 页码:7943-7955]

2126918-57-6 + 6069-06-3 = 87233-61-2
反应条件:1.1 Reagents: Sodium Hydride Solvents: Dimethyl Sulfoxide; Rt; 15 Min,Rt1.2 Solvents: Dimethyl Sulfoxide; 24 H,Rt; 60 Min,Rt1.3 Reagents: Water1.4 Reagents: Pivalic Acid Catalysts: Copper Bis(Ethyl Acetylacetate) Solvents: Sulfolane; 30 H,1 Atm,Rt -> 100 °C1.5 Reagents: Sodium Hydride Solvents: Tetrahydrofuran; 15 Min,Rt; 15 Min,Rt1.6 Solvents: Tetrahydrofuran; 18 H,Rt -> Reflux; 60 Min,Reflux; Reflux -> Rt1.7 Reagents: Water1.8 Reagents: Hydrochloric Acid Solvents: Ethyl Acetate; 64 H,Rt1.9 Reagents: Sodium Bicarbonate Solvents: Water1.10 Reagents: Formic Acid Solvents: Water; 30 Min,80 °C1.11 Reagents: Sodium Hydroxide Solvents: Water; Ph 10
标题:Copper-Catalysed C-H Functionalisation Gives Access To 2-Aminobenzimidazoles
作者:Clark,Peter R.; Et Al
参考文献:Organic & Biomolecular Chemistry 日期:2019 卷标:17(34) 页码:7943-7955]

112275-50-0 = 87233-61-2
反应条件:1.1 Reagents: Diisopropylethylamine Solvents: Chloroform; 0 °C -> Rt; 4 H,Rt1.2 Reagents: Sodium Hydroxide Solvents: Water2.1 Reagents: Sodium Hydride Solvents: Dimethyl Sulfoxide; Rt; 15 Min,Rt2.2 Solvents: Dimethyl Sulfoxide; 24 H,Rt; 60 Min,Rt2.3 Reagents: Water2.4 Reagents: Pivalic Acid Catalysts: Copper Bis(Ethyl Acetylacetate) Solvents: Sulfolane; 30 H,1 Atm,Rt -> 100 °C2.5 Reagents: Sodium Hydride Solvents: Tetrahydrofuran; 15 Min,Rt; 15 Min,Rt2.6 Solvents: Tetrahydrofuran; 18 H,Rt -> Reflux; 60 Min,Reflux; Reflux -> Rt2.7 Reagents: Water2.8 Reagents: Hydrochloric Acid Solvents: Ethyl Acetate; 64 H,Rt2.9 Reagents: Sodium Bicarbonate Solvents: Water2.10 Reagents: Formic Acid Solvents: Water; 30 Min,80 °C2.11 Reagents: Sodium Hydroxide Solvents: Water; Ph 10
标题:Copper-Catalysed C-H Functionalisation Gives Access To 2-Aminobenzimidazoles
作者:Clark,Peter R.; Et Al
参考文献:Organic & Biomolecular Chemistry 日期:2019 卷标:17(34) 页码:7943-7955]

192940-60-6 + 6069-06-3 = 87233-61-2
反应条件:1.1 Reagents: Sodium Hydride Solvents: Tetrahydrofuran; 15 Min,Rt; 15 Min,Rt1.2 Solvents: Tetrahydrofuran; 18 H,Rt -> Reflux; 60 Min,Reflux; Reflux -> Rt1.3 Reagents: Water2.1 Reagents: Hydrochloric Acid Solvents: Ethyl Acetate; 64 H,Rt2.2 Reagents: Sodium Bicarbonate Solvents: Water2.3 Reagents: Formic Acid Solvents: Water; 30 Min,80 °C2.4 Reagents: Sodium Hydroxide Solvents: Water; Ph 10
标题:Copper-Catalysed C-H Functionalisation Gives Access To 2-Aminobenzimidazoles
作者:Clark,Peter R.; Et Al
参考文献:Organic & Biomolecular Chemistry 日期:2019 卷标:17(34) 页码:7943-7955]

2375311-04-7 = 87233-61-2
反应条件:1.1 Reagents: Hydrochloric Acid Solvents: Ethyl Acetate; 64 H,Rt1.2 Reagents: Sodium Bicarbonate Solvents: Water2.1 Reagents: Formic Acid Solvents: Water; 30 Min,80 °C2.2 Reagents: Sodium Hydroxide Solvents: Water; Ph 10
标题:Copper-Catalysed C-H Functionalisation Gives Access To 2-Aminobenzimidazoles
作者:Clark,Peter R.; Et Al
参考文献:Organic & Biomolecular Chemistry 日期:2019 卷标:17(34) 页码:7943-7955]

2375311-03-6 = 87233-61-2
反应条件:1.1 Reagents: Pivalic Acid Catalysts: Copper Bis(Ethyl Acetylacetate) Solvents: Sulfolane; 30 H,1 Atm,Rt -> 100 °C2.1 Reagents: Sodium Hydride Solvents: Tetrahydrofuran; 15 Min,Rt; 15 Min,Rt2.2 Solvents: Tetrahydrofuran; 18 H,Rt -> Reflux; 60 Min,Reflux; Reflux -> Rt2.3 Reagents: Water3.1 Reagents: Hydrochloric Acid Solvents: Ethyl Acetate; 64 H,Rt3.2 Reagents: Sodium Bicarbonate Solvents: Water3.3 Reagents: Formic Acid Solvents: Water; 30 Min,80 °C3.4 Reagents: Sodium Hydroxide Solvents: Water; Ph 10
标题:Copper-Catalysed C-H Functionalisation Gives Access To 2-Aminobenzimidazoles
作者:Clark,Peter R.; Et Al
参考文献:Organic & Biomolecular Chemistry 日期:2019 卷标:17(34) 页码:7943-7955]

2126918-57-6 = 87233-61-2
反应条件:1.1 Reagents: Sodium Hydride Solvents: Dimethyl Sulfoxide; Rt; 15 Min,Rt1.2 Solvents: Dimethyl Sulfoxide; 24 H,Rt; 60 Min,Rt1.3 Reagents: Water2.1 Reagents: Pivalic Acid Catalysts: Copper Bis(Ethyl Acetylacetate) Solvents: Sulfolane; 30 H,1 Atm,Rt -> 100 °C3.1 Reagents: Sodium Hydride Solvents: Tetrahydrofuran; 15 Min,Rt; 15 Min,Rt3.2 Solvents: Tetrahydrofuran; 18 H,Rt -> Reflux; 60 Min,Reflux; Reflux -> Rt3.3 Reagents: Water4.1 Reagents: Hydrochloric Acid Solvents: Ethyl Acetate; 64 H,Rt4.2 Reagents: Sodium Bicarbonate Solvents: Water4.3 Reagents: Formic Acid Solvents: Water; 30 Min,80 °C4.4 Reagents: Sodium Hydroxide Solvents: Water; Ph 10
标题:Copper-Catalysed C-H Functionalisation Gives Access To 2-Aminobenzimidazoles
作者:Clark,Peter R.; Et Al
参考文献:Organic & Biomolecular Chemistry 日期:2019 卷标:17(34) 页码:7943-7955]

101953-61-1 = 87233-61-2 + 110-17-8
反应条件:1.1 Reagents: Phosphorus Oxychloride2.1 -
标题:Synthesis Of 2-(4-Substituted-1-Piperazinyl)Benzimidazoles As H1-Antihistaminic Agents
作者:Iemura,Ryuichi; Et Al
参考文献:Journal Of Medicinal Chemistry 日期:1986 卷标:29(7) 页码:1178-83]

57-13-6 + 95893-89-3 = 87233-61-2 + 110-17-8
反应条件:1.1 -2.1 Reagents: Phosphorus Oxychloride3.1 -
标题:Synthesis Of 2-(4-Substituted-1-Piperazinyl)Benzimidazoles As H1-Antihistaminic Agents
作者:Iemura,Ryuichi; Et Al
参考文献:Journal Of Medicinal Chemistry 日期:1986 卷标:29(7) 页码:1178-83]

95893-88-2 = 87233-61-2 + 110-17-8
反应条件:1.1 Reagents: Sodium Hydroxide,Zinc Solvents: Ethanol,Water2.1 -3.1 Reagents: Phosphorus Oxychloride4.1 -
标题:Synthesis Of 2-(4-Substituted-1-Piperazinyl)Benzimidazoles As H1-Antihistaminic Agents
作者:Iemura,Ryuichi; Et Al
参考文献:Journal Of Medicinal Chemistry 日期:1986 卷标:29(7) 页码:1178-83

N-(2-乙氧基乙基)-2-硝基-苯胺置于sodium Hydroxide,锌,三氯氧磷体系中,用乙醇作为反应溶剂,化学反应 9.5H,反应生成依美司丁
参考文献:合成作为h1抗组胺药的2-(4-取代-1-哌嗪基)苯并咪唑.
标题:合成作为h1抗组胺药的2-(4-取代-1-哌嗪基)苯并咪唑.
摘要:制备了一系列的2-(4-取代的-1-(高)哌嗪基)苯并咪唑,并在体内和体外测试了h1-抗组胺活性.大多数化合物显示出抗组胺活性,而某些1-[2-(取代-氧基)乙基]衍生物则显示出有效的活性.在结构活性比较中,发现苯并咪唑核的1-位上的2-(取代-氧)乙基中的氧原子对于有效的抗组胺活性,特别是在体内具有重要作用.最有效的化合物之一1-(2-乙氧基乙基)-2-(4-甲基-1-高哌嗪基)苯并咪唑(69)的体内h1抗组胺活性比马来酸氯苯那敏高39倍,因此被选作临床评估.
DOI:10.1021/jm00157A010

海关参考信息

2902200000-苯
2909110000-乙醚
2921211000-乙二胺
2901100000-饱和无环烃
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:US-8734846-B2
优先权日:2008-06-16
标题 :Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
发明人：ALI MIR M; HRKACH JEFF; ZALE STEPHEN E; ALVAREZ DE CIENFUEGOS LUIS
权利人:BIND BIOSCIENCES INC
摘要:This application provides nanoparticles and methods of making nanoparticles using pre-functionalized poly(ethylene glycol)(also referred to as PEG) as a macroinitiator for the synthesis of diblock copolymers. Ring opening polymerization yields the desired poly(ester)-poly (ethylene glycol)-targeting agent polymer that is used to impart targeting capability to therapeutic nanoparticles. This â€œpolymerization fromâ€? approach typically employs precursors of the targeting agent wherein the reactivity of functional groups of the targeting agent is masked using protecting groups. Also described is a â€œcoupling toâ€? that utilized the poly(ethylene glycol)-targeting agent conjugate where the targeting agent remains in its native un-protected form. This method uses â€œorthogonalâ€? chemistry that exhibit no cross reactivity towards functional groups typically found within targeting agents of interest.

专利号:WO-2023075715-A1
优先权日:2021-10-26
标题 :A pharmaceutical formulation including leukotriene receptor antagonists and/or leukotriene synthesis inhibitors combined with non-steroidal anti-inflammatory drugs (nsaids)
发明人：OYTUN FARUK; CAN EFE
权利人:VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI
摘要:This invention is related to a pharmaceutical formulation including Leukotriene receptor antagonists and/or Leukotriene synthesis inhibitors combined with non-steroidal anti-inflammatory drugs (NSAIDs) and antihistamines in ocular diseases and in inflammatory and allergic diseases for systemic and topical use. The objective of this invention is to create a novel formulation to be effective as much as steroids while having significantly less side effects for long-term use in treating ocular diseases, inflammatory and allergic diseases. In other words our aim is to achieve the inhibition of pro-inflammatory mediators (prostaglandins, thromboxane, histamine and leukotrienes) as much as steroids do with a safer combination.

专利号:US-2007148246-A1
优先权日:2005-08-11
标题:Nucleic Acid-Based Matrixes
发明人：LUO DAN; LI YOUGEN
权利人:LUO DAN; LI YOUGEN
摘要:Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. Methods of utilizing such biomaterials include delivery of biologically active agents, cell and tissue culture, and cell-free protein synthesis.

专利号:US-2014315720-A1
优先权日:2012-10-24
标题 :Polysaccharide ester microspheres and methods and articles relating thereto
发明人：FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY
权利人:CELANESE ACETATE LLC
摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.

专利号:US-2012232031-A1
优先权日:2009-10-19
标题:Injectable formulations for intra-articular or peri-articular administration
发明人：HUTCHINSON JOHN HOWARD; PRASIT PETPIBOON PEPPI; DEARMOND ISABELLE MARGUERITE
权利人:HUTCHINSON JOHN HOWARD; PRASIT PETPIBOON PEPPI; DEARMOND ISABELLE MARGUERITE; PANMIRA PHARMACEUTICALS LLC
摘要:Described herein are injectable formulations for intra-articular or peri-articular administration, wherein the formulation is administered to treat joint pain. An injectable formulation for intra-articular or peri-articular administration disclosed herein comprises a therapeutically-effective amount of a leukotriene synthesis inhibitor compound formulated for intra-articular or peri-articular administration.

专利号:CN-107935938-A
优先权日:2017-12-22
标题 :A kind of chemical synthesis method of 2-hydroxybenzimidazole

其他信息查阅

苏州正永生物医药有限公司

网址: http://www.xeonpharm.com
电话: 0512-67302433👤

⚠️ 未注册 · 未认证企业

备注: 📌 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议，请通过页面底部联系方式告知我们，我们会尽快处理。

济南福方化工有限公司

网址: http://www.fufangchem.com
企业联系电话：0531-66593191/13082737003👤
地址:济南市中区岔路街308号

⚠️ 未注册 · 未认证企业

备注: 📌 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议，请通过页面底部联系方式告知我们，我们会尽快处理。

第 1 / 1 页

现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

合成参考文献

摘要:S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (2021) DOI:10.1021/acsenvironau.1c00008. List downloaded from
参考文献:10.1177/026988110201600104
摘要:Vermeeren A, Ramaekers JG, O'Hanlon JF. Effects of emedastine and cetirizine, alone and with alcohol, on actual driving of males and females. J Psychopharmacol. 2002 Mar;16(1):57–64. doi: 10.1177/026988110201600104.
参考文献:10.1016/s0149-2918(02)85042-1
摘要:D'Arienzo PA, Leonardi A, Bensch G. Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther. 2002 Mar;24(3):409–16. doi: 10.1016/s0149-2918(02)85042-1.
参考文献:10.1016/s0149-2918(02)85045-7
摘要:Abelson MB, Kaplan AP. A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge model. Clin Ther. 2002 Mar;24(3):445–56. doi: 10.1016/s0149-2918(02)85045-7.

📝 需求与反馈

📲 手机号 / 邮箱 *

✏️ 问题内容 *

尽可能描述清楚需求与问题信息